Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.
Riganti C, et al. Among authors: novello s.
Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.
Oncoimmunology. 2017.
PMID: 29399399
Free PMC article.